Long-term findings from the pivotal study of Medtronic’s Extravascular Implantable Cardioverter Defibrillator (EV ICD), including patients followed through an average of 17 months, showed that the system frequently terminates tachycardia with pacing instead of a defibrillator shock.
Medtronic's EV ICD
Like other "leadless" cardiac rhythm management devices, Medtronic's EV ICD avoids some of the risks of traditional, transvenous ICDs with a lead installed under the sternum instead of in a vein in the heart.
The generator is implanted in the left mid-axillary region below the left armpit. The system also offers anti-tachycardia pacing (ATP), pause-prevention pacing, and a device similar in size, shape, and battery longevity to transvenous ICDs.
The EV ICD system is not yet approved for sale or distribution in the US, it is available in Europe under the brand name Aurora EV ICD. (Also see "Minute Insight: Medtronic’s Extravascular ICD Earns European Approval" - Medtech Insight, 21 February, 2023.)
It competes directly with Boston Scientific's Emblem MRI subcutaneous ICD. (Also see "Medtronic’s Extravascular ICD Hits Targets In Trial; Will Soon Compete With Boston Scientific’s S-ICD" - Medtech Insight, 31 August, 2022.)
EV ICD complements Medtronic's Micra line of leadless pacemakers. (Also see "Minute Insight: Medtronic Counters Abbott With New Micra Leadless Pacemakers" - Medtech Insight, 1 May, 2023.)
Principal Investigator Paul Friedman of the Mayo Clinic in Minnesota presented the long-term results at Heart Rhythm 2023 on 20...
